Clinical and neuroimaging findings in MOGAD-MRI and OCT
- PMID: 34152000
- PMCID: PMC8561692
- DOI: 10.1111/cei.13641
Clinical and neuroimaging findings in MOGAD-MRI and OCT
Abstract
Myelin oligodendrocyte glycoprotein antibody-associated disorders (MOGAD) are rare in both children and adults, and have been recently suggested to be an autoimmune neuroinflammatory group of disorders that are different from aquaporin-4 autoantibody-associated neuromyelitis optica spectrum disorder and from classic multiple sclerosis. In-vivo imaging of the MOGAD patient central nervous system has shown some distinguishing features when evaluating magnetic resonance imaging of the brain, spinal cord and optic nerves, as well as retinal imaging using optical coherence tomography. In this review, we discuss key clinical and neuroimaging characteristics of paediatric and adult MOGAD. We describe how these imaging techniques may be used to study this group of disorders and discuss how image analysis methods have led to recent insights for consideration in future studies.
Keywords: magnetic resonance imaging; myelin oligodendrocyte glycoprotein associated disorders; optical coherence tomography.
© 2021 The Authors. Clinical & Experimental Immunology published by John Wiley & Sons Ltd on behalf of British Society for Immunology.
Conflict of interest statement
F. Bartels is supported by the Berlin Institute of Health (BIH) and the Berlin School of Mind and Brain, both unrelated to this review. A. Lu has no disclosures to report. F. C. Oertel receives research support from the American Academy of Neurology (AAN) unrelated to this review. C. Finke receives research funding by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation; grant numbers FI 2309/1‐1 and FI 2309/2‐1) and the German Ministry of Education and Research (BMBF, grant number 01GM1908D; CONNECT‐GENERATE) unrelated to this review. F. Paul is named as co‐inventor on the patent application for the foveal shape analysis method (‘Method for estimating shape parameters of the fovea byoptical coherence tomography’, International Publication number: ‘WO 2019/016319 A1’), is a co‐founder and holds shares in technology start‐up Nocturne GmbH, receives honoraria for lecturing and travel expenses for attending meetings from Guthy Jackson Foundation, Bayer, Biogen, Merck Serono, Sanofi Genzyme, Novartis, Alexion, Viela Bio, Roche, UCB, Mitsubishi Tanabe and Celgene. His research is funded by the German Ministry for Education and Research (BMBF), Deutsche Forschungsgemeinschaft (DFG), Einstein Foundation, Guthy Jackson Charitable Foundation, EU FP7 Framework Program, Biogen, Genzyme, Merck Serono, Novartis, Bayer, Alexion, Roche, Parexel and Almirall. C. Chien has received speaking fees from Bayer and research support from Novartis unrelated to this review.
Figures
References
-
- Reindl M, Waters P. Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nat Rev Neurol. 2019;15:89–102. - PubMed
-
- Narayan R, Simpson A, Fritsche K, Salama S, Pardo S, Mealy M, et al. MOG antibody disease: a review of MOG antibody seropositive neuromyelitis optica spectrum disorder. Mult Scler Relat Disord. 2018;1:66–72. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
